Have a feature idea you'd love to see implemented?
Let us know!
NEO Neogenomics Inc
Price (delayed)
$15.39
Market cap
$1.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
$2.22B
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose
Highlights
The company's EPS rose by 21% YoY
Neogenomics's gross profit has increased by 20% YoY and by 4.7% QoQ
The quick ratio has plunged by 68% YoY
The equity is down by 4.1% year-on-year
Key stats
What are the main financial stats of NEO
Market
Valuations
Earnings
Shares outstanding
128.36M
Market cap
$1.98B
Enterprise value
$2.22B
Price to book (P/B)
2.17
Price to sales (P/S)
3.03
EV/EBIT
N/A
EV/EBITDA
105.63
EV/Sales
3.45
Revenue
$644.12M
EBIT
-$61.1M
EBITDA
$21.02M
Free cash flow
-$21.51M
Per share
Balance sheet
Liquidity
EPS
-$0.61
Free cash flow per share
-$0.17
Book value per share
$7.09
Revenue per share
$5.07
TBVPS
$6.07
Total assets
$1.64B
Total liabilities
$732.9M
Debt
$606.27M
Equity
$908.21M
Working capital
$293.84M
Debt to equity
0.67
Current ratio
1.99
Quick ratio
1.82
Net debt/EBITDA
11.62
Margins
Efficiency
Dividend
EBITDA margin
3.3%
Gross margin
43.5%
Net margin
-12.1%
Operating margin
-14.3%
Return on assets
-4.7%
Return on equity
-8.4%
Return on invested capital
-7.3%
Return on capital employed
-4.5%
Return on sales
-9.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NEO stock price
How has the Neogenomics stock price performed over time
Intraday
0.2%
1 week
-2.53%
1 month
17.21%
1 year
-19.76%
YTD
-4.88%
QTD
4.34%
Financial performance
How have Neogenomics's revenue and profit performed over time
Revenue
$644.12M
Gross profit
$280.43M
Operating income
-$92.28M
Net income
-$77.73M
Gross margin
43.5%
Net margin
-12.1%
Neogenomics's operating margin has increased by 29% YoY and by 6% from the previous quarter
NEO's net margin is up by 28% YoY and by 3.2% QoQ
The company's operating income rose by 20% YoY and by 3.1% QoQ
Neogenomics's gross profit has increased by 20% YoY and by 4.7% QoQ
Growth
What is Neogenomics's growth rate over time
Valuation
What is Neogenomics stock price valuation
P/E
N/A
P/B
2.17
P/S
3.03
EV/EBIT
N/A
EV/EBITDA
105.63
EV/Sales
3.45
The company's EPS rose by 21% YoY
The price to book (P/B) is 38% less than the 5-year quarterly average of 3.5 but 3.3% more than the last 4 quarters average of 2.1
The equity is down by 4.1% year-on-year
The price to sales (P/S) is 50% lower than the 5-year quarterly average of 6.1 and 2.3% lower than the last 4 quarters average of 3.1
The revenue rose by 12% YoY and by 2.5% QoQ
Efficiency
How efficient is Neogenomics business performance
The company's return on sales rose by 44% YoY and by 8% QoQ
NEO's ROIC is up by 23% year-on-year
The return on assets rose by 16% year-on-year
The return on equity has increased by 15% year-on-year
Dividends
What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NEO.
Financial health
How did Neogenomics financials performed over time
The total assets is 124% greater than the total liabilities
NEO's current ratio has plunged by 69% YoY
The quick ratio has plunged by 68% YoY
NEO's debt is 33% lower than its equity
The debt to equity rose by 4.7% year-on-year
The equity is down by 4.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.